Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMGN NASDAQ:GILD NASDAQ:LGND NASDAQ:MRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$331.57+0.2%$347.53$267.83▼$391.29$178.94B0.442.76 million shs4.07 million shsGILDGilead Sciences$130.69+0.1%$137.18$104.46▼$157.29$162.26B0.316.73 million shs5.57 million shsLGNDLigand Pharmaceuticals$217.75+4.8%$214.63$98.89▼$247.38$4.36B1.2224,217 shs260,297 shsMRNAModerna$48.12+5.2%$51.31$22.28▼$59.55$19.09B1.059.68 million shs4.77 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+1.96%-1.65%-6.91%-12.90%+19.90%GILDGilead Sciences+0.64%-3.29%-5.19%-14.56%+22.93%LGNDLigand Pharmaceuticals-0.05%-6.41%-10.37%+9.39%+97.30%MRNAModerna-4.97%-14.17%-14.89%-1.89%+73.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$331.57+0.2%$347.53$267.83▼$391.29$178.94B0.442.76 million shs4.07 million shsGILDGilead Sciences$130.69+0.1%$137.18$104.46▼$157.29$162.26B0.316.73 million shs5.57 million shsLGNDLigand Pharmaceuticals$217.75+4.8%$214.63$98.89▼$247.38$4.36B1.2224,217 shs260,297 shsMRNAModerna$48.12+5.2%$51.31$22.28▼$59.55$19.09B1.059.68 million shs4.77 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen+1.96%-1.65%-6.91%-12.90%+19.90%GILDGilead Sciences+0.64%-3.29%-5.19%-14.56%+22.93%LGNDLigand Pharmaceuticals-0.05%-6.41%-10.37%+9.39%+97.30%MRNAModerna-4.97%-14.17%-14.89%-1.89%+73.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMGNAmgen 2.48Hold$355.197.12% UpsideGILDGilead Sciences 2.86Moderate Buy$156.9320.07% UpsideLGNDLigand Pharmaceuticals 2.88Moderate Buy$257.7118.35% UpsideMRNAModerna 1.84Reduce$35.73-25.74% DownsideCurrent Analyst Ratings BreakdownLatest GILD, AMGN, LGND, and MRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026AMGNAmgen ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$400.00 ➝ $375.005/20/2026GILDGilead Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$165.005/19/2026GILDGilead Sciences Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$161.00 ➝ $150.005/15/2026LGNDLigand Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/14/2026AMGNAmgen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$432.00 ➝ $427.005/13/2026AMGNAmgen Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$410.00 ➝ $390.005/11/2026GILDGilead Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/11/2026GILDGilead Sciences Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$170.00 ➝ $167.005/8/2026GILDGilead Sciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$175.00 ➝ $168.005/8/2026GILDGilead Sciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$148.00 ➝ $146.005/8/2026GILDGilead Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$155.00 ➝ $157.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMGNAmgen$37.22B4.81$34.54 per share9.60$17.03 per share19.47GILDGilead Sciences$29.74B5.46$10.55 per share12.39$18.87 per share6.93LGNDLigand Pharmaceuticals$268.09M16.28$8.22 per share26.48$49.76 per share4.38MRNAModerna$2.20B8.66N/AN/A$18.67 per share2.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMGNAmgen$7.71B$14.3723.0714.093.2620.96%137.41%13.28%8/4/2026 (Estimated)GILDGilead Sciences$8.51B$7.3417.8113.59N/A30.99%48.19%18.28%8/6/2026 (Estimated)LGNDLigand Pharmaceuticals$124.45M$7.3729.5529.071.6855.95%16.19%11.13%8/6/2026 (Estimated)MRNAModerna-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)Latest GILD, AMGN, LGND, and MRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LGNDLigand Pharmaceuticals$1.84$1.63-$0.21-$0.67$59.10 million$51.72 million5/7/2026Q1 2026GILDGilead Sciences$1.91$2.03+$0.12$1.61$6.91 billion$6.96 billion5/1/2026Q1 2026MRNAModerna-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million4/30/2026Q1 2026AMGNAmgen$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion2/26/2026Q4 2025LGNDLigand Pharmaceuticals$1.46$2.02+$0.56$2.12$55.59 million$59.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMGNAmgen$10.083.04%+8.27%70.15%14 YearsGILDGilead Sciences$3.282.52%+3.04%44.69%10 YearsLGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMRNAModernaN/AN/AN/AN/AN/ALatest GILD, AMGN, LGND, and MRNA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GILDGilead Sciencesquarterly$0.822.45%6/15/20266/15/20266/29/20263/4/2026AMGNAmgenquarterly$2.523.09%5/15/20265/15/20266/5/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMGNAmgen5.651.261.01GILDGilead Sciences0.891.971.77LGNDLigand Pharmaceuticals0.4521.2820.95MRNAModerna0.082.412.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMGNAmgen76.50%GILDGilead Sciences83.67%LGNDLigand Pharmaceuticals91.28%MRNAModerna75.33%Insider OwnershipCompanyInsider OwnershipAMGNAmgen0.85%GILDGilead Sciences0.30%LGNDLigand Pharmaceuticals7.00%MRNAModerna10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMGNAmgen31,500539.69 million535.10 millionOptionableGILDGilead Sciences17,0001.24 billion1.24 billionOptionableLGNDLigand Pharmaceuticals8020.04 million18.64 millionOptionableMRNAModerna4,700396.79 million353.93 millionOptionableGILD, AMGN, LGND, and MRNA HeadlinesRecent News About These CompaniesPfizer, Moderna COVID vaccines 70% to 76% effective against severe illness in kids in 2022, data suggestMay 19 at 12:51 AM | cidrap.umn.eduCHHS cancels funding for Moderna vaccines to fight pandemic fluMay 19 at 2:48 PM | msn.comModerna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 1:03 PM | seekingalpha.comModerna (NASDAQ:MRNA) President Stephen Hoge Sells 53,336 SharesMay 19 at 4:01 AM | insidertrades.comModerna Reports Second Quarter 2025 Financial Results and Provides Business UpdatesMay 18 at 8:02 AM | freep.comFModerna Reports Third Quarter 2025 Financial Results and Provides Business UpdatesMay 17 at 9:31 AM | freep.comFAssessing Moderna (MRNA) Valuation After Flu Vaccine Trial Success And Hantavirus Research AttentionMay 16, 2026 | finance.yahoo.comHantavirus: Is there a risk of another pandemic?May 16, 2026 | finance.yahoo.comVIRGINIA RETIREMENT SYSTEMS ET Al Purchases 23,550 Shares of Moderna, Inc. $MRNAMay 16, 2026 | marketbeat.comSlowed But Not Stalled: The Future of mRNA Vaccine ResearchMay 14, 2026 | the-scientist.comTModerna Recognized by TIME as One of the World’s Most Impactful CompaniesMay 13, 2026 | usatoday.com3 Reasons Not to Buy Into the Hantavirus-Related Biotech RallyMay 13, 2026 | fool.comModerna (MRNA) Shares Skyrocket, What You Need To KnowMay 13, 2026 | finance.yahoo.comModerna, Inc.: Moderna Recognized by TIME as One of the World's Most Impactful CompaniesMay 12, 2026 | finanznachrichten.deModerna Recognized by TIME as One of the World's Most Impactful CompaniesMay 12, 2026 | finance.yahoo.comModerna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comModerna Recognized by TIME as One of the World's Most Impactful CompaniesMay 12, 2026 | accessnewswire.comAModerna's Revenues See Strong International Momentum in Q1 EarningsMay 12, 2026 | finance.yahoo.comModerna's AI Could Get a Hantavirus Vaccine Here FasterMay 12, 2026 | pymnts.comModerna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong SellMay 12, 2026 | seekingalpha.comModerna stock extends gains on hantavirus researchMay 11, 2026 | aol.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeGILD, AMGN, LGND, and MRNA Company DescriptionsAmgen NASDAQ:AMGN$331.57 +0.82 (+0.25%) Closing price 04:00 PM EasternExtended Trading$332.00 +0.43 (+0.13%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Gilead Sciences NASDAQ:GILD$130.69 +0.19 (+0.15%) Closing price 04:00 PM EasternExtended Trading$131.04 +0.34 (+0.26%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.Ligand Pharmaceuticals NASDAQ:LGND$217.75 +9.97 (+4.80%) Closing price 04:00 PM EasternExtended Trading$218.16 +0.41 (+0.19%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Moderna NASDAQ:MRNA$48.12 +2.40 (+5.25%) Closing price 04:00 PM EasternExtended Trading$48.14 +0.03 (+0.05%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
